Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Grant Approvals Cprit topic
No spam. Unsubscribe anytime.
CPRIT oversight committee approves 53 academic research awards totaling $67.8 million and several administrative actions
Summary
The CPRIT Oversight Committee approved a slate of 53 academic research awards totaling $67,800,000, delegated contract authority to the CEO, approved a product development RFA package for FY2026, and adopted rule changes to Texas Administrative Code Chapter 703.
The Cancer Prevention and Research Institute of Texas (CPRIT) Oversight Committee approved 53 academic research award recommendations totaling $67,800,000 and took several related administrative actions during its meeting.
The committee voted to approve the academic research slate after a separate, recorded vote on one application (RP 250278) for which Dr. Rosenfeld reported a conflict of interest and did not vote on that item. The chair called for approval of the remaining 52 recommendations by slate; members voted in favor and the motion carried by the required two‑thirds of members present and voting.
Why this matters: the awards support investigator‑initiated research, recruitment of investigators and core facilities across Texas and address priorities including hepatocellular carcinoma, childhood and adolescent cancers, computational oncology, clinical trials proposals and prevention/early detection projects.
Other formal actions taken by the committee: - Delegated contract authority: The committee voted to authorize the CPRIT CEO and staff to negotiate and sign contracts on behalf of CPRIT for the approved awards and grants. The motion carried. - Product development RFAs: The committee approved CPRIT’s proposed FY2026 product development requests for applications (RFAs), which include three uncapped full‑company award mechanisms (therapeutics; devices and diagnostics; and new technologies) and a seed award capped at $3,000,000 for up to 3 years. The committee also approved a supplemental FY25.2 award mechanism with $10.3 million available to bridge selected existing product development awardees. - Rule adoption: The committee approved a final order adopting changes to Texas Administrative Code, Chapter 703, as presented earlier at the November meeting; no public comments were received during the required notice period. - Committee appointments and administrative items: The committee approved the CEO’s appointments to the Scientific Research and Prevention Program Committees and three appointments to the Clinical Trials Advisory Committee, and accepted other routine reports including the CEO and chief compliance officer reports.
Votes and recusals: The record shows the separate handling of RP 250278 (a single application) and that Dr. Rosenfeld recused from voting on that item. For other slates the chair called for a single vote to approve all remaining recommendations; members voted aye and the motion carried by the required supermajority.
Financial and program context presented to the committee during the meeting included: - The academic slate covers fiscal year 2024 review cycle 2 and FY25 review cycle 1 and recruitment cycles for FY25 cycles 2 and 3, and includes recruitment awards and core facility support. - CPRIT staff reported that, to date, CPRIT has awarded nearly 2,100 grants across Texas, manages approximately $1.5 billion in grants under management with about 540 active grants at any time, and has 53 full‑time employees (reporting the agency is above its current FTE cap). - The chief compliance officer reported enhanced review activity for product development match expenditures (about $33 million reviewed this fiscal year) and a low rate of unallowable match findings so far.
The committee approved motions delegating authority to the CEO for contract execution and to proceed with the recommended awards and RFAs. The oversight committee also approved the final order to adopt administrative rule changes and closed the meeting after a scheduled closed session.
